{"id":"https://openalex.org/W6983467665","doi":null,"title":"M\u00e9tabolites circulants de la voie du tryptophane et r\u00e9ponse \u00e0 l'immunoth\u00e9rapie chez les patients atteints de cancer : valeur pr\u00e9dictive et m\u00e9canisme de r\u00e9sistance","display_name":"M\u00e9tabolites circulants de la voie du tryptophane et r\u00e9ponse \u00e0 l'immunoth\u00e9rapie chez les patients atteints de cancer : valeur pr\u00e9dictive et m\u00e9canisme de r\u00e9sistance","alternate_titles":[],"publication_year":2021,"publication_date":"2021-09-21","ids":{"openalex":"https://openalex.org/W6983467665"},"language":"en","primary_location":{"id":"pmh:oai:HAL:dumas-03352840v1","doi":null,"is_oa":true,"landing_page_url":"https://hal.science/dumas-03352840v1","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Sciences du Vivant [q-bio]. 2021","raw_type":"info:eu-repo/semantics/masterThesis"},"parent_works":[],"lineage":["https://openalex.org/W6983467665"],"child_works_count":0,"type":"dissertation","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://hal.science/dumas-03352840v1","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5009157549","display_name":"Florent Peyraud","orcid":"https://orcid.org/0000-0001-7438-2847","observed_orcids":["https://orcid.org/0000-0001-7438-2847"]},"institutions":[{"id":"https://openalex.org/I15057530","display_name":"Universit\u00e9 de Bordeaux","ror":"https://ror.org/057qpr032","country_code":"FR","type":"education","lineage":["https://openalex.org/I15057530"]}],"countries":["FR"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Peyraud, Florent","raw_affiliation_strings":["UB - Universit\u00e9 de Bordeaux (35, place Pey Berland - 33076 Bordeaux - France)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UB - Universit\u00e9 de Bordeaux (35, place Pey Berland - 33076 Bordeaux - France)","institution_ids":["https://openalex.org/I15057530"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5009157549"],"corresponding_institution_ids":["https://openalex.org/I15057530"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":true,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11337","display_name":"Tryptophan and brain disorders","score":0.014999999664723873,"subfield":{"id":"https://openalex.org/subfields/2803","display_name":"Biological Psychiatry"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tryptophan-metabolism","display_name":"tryptophan metabolism","score":0.8859999775886536},{"id":"https://openalex.org/keywords/kynurenine","display_name":"kynurenine","score":0.902999997138977},{"id":"https://openalex.org/keywords/tryptophan","display_name":"tryptophan","score":0.8389999866485596},{"id":"https://openalex.org/keywords/ido1","display_name":"IDO1","score":0.8669999837875366},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9539999961853027},{"id":"https://openalex.org/keywords/pd-1-pd-l1-blockade","display_name":"PD-1/PD-L1 blockade","score":0.781000018119812},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.6700000166893005},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.800000011920929},{"id":"https://openalex.org/keywords/treatment-resistance","display_name":"treatment resistance","score":0.6830000281333923},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.7039999961853027},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.9039999842643738},{"id":"https://openalex.org/keywords/circulating-metabolites","display_name":"circulating metabolites","score":0.7099999785423279},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.6029999852180481},{"id":"https://openalex.org/keywords/survival-outcomes","display_name":"survival outcomes","score":0.32100000977516174}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7574999928474426},{"id":"https://openalex.org/C2777503454","wikidata":"https://www.wikidata.org/wiki/Q415768","display_name":"Kynurenine","level":4,"score":0.5824000239372253},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.5591999888420105},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5476999878883362},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.5282999873161316},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.508400022983551},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5034999847412109},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.48570001125335693},{"id":"https://openalex.org/C188816634","wikidata":"https://www.wikidata.org/wiki/Q2113324","display_name":"Prospective cohort study","level":2,"score":0.43230000138282776},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.4320000112056732},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4316999912261963},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.41119998693466187},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.39559999108314514},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.367000013589859},{"id":"https://openalex.org/C2776706248","wikidata":"https://www.wikidata.org/wiki/Q181003","display_name":"Tryptophan","level":3,"score":0.34369999170303345},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.3334999978542328},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3147999942302704},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.29840001463890076},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.2980000078678131},{"id":"https://openalex.org/C2908944834","wikidata":"https://www.wikidata.org/wiki/Q181003","display_name":"Tryptophan Metabolism","level":4,"score":0.29409998655319214},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.2849000096321106},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.2639000117778778},{"id":"https://openalex.org/C63363279","wikidata":"https://www.wikidata.org/wiki/Q5133848","display_name":"Clinical significance","level":2,"score":0.2599000036716461}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:HAL:dumas-03352840v1","doi":null,"is_oa":true,"landing_page_url":"https://hal.science/dumas-03352840v1","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Sciences du Vivant [q-bio]. 2021","raw_type":"info:eu-repo/semantics/masterThesis"}],"best_oa_location":{"id":"pmh:oai:HAL:dumas-03352840v1","doi":null,"is_oa":true,"landing_page_url":"https://hal.science/dumas-03352840v1","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Sciences du Vivant [q-bio]. 2021","raw_type":"info:eu-repo/semantics/masterThesis"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3040791408","https://openalex.org/W2886009445","https://openalex.org/W3034797925","https://openalex.org/W4390307768","https://openalex.org/W4212902132","https://openalex.org/W4409626455","https://openalex.org/W2976621574","https://openalex.org/W3097655266","https://openalex.org/W4379333497","https://openalex.org/W2599400888"],"abstract_inverted_index":{"Introduction:":[0],"despite":[1],"remarkable":[2],"success":[3],"of":[4,24,46,68,96,110,117,137,220,263,282,296,303,325],"immune":[5],"checkpoint":[6],"inhibitors":[7],"(ICIs)":[8],"targeting":[9,310],"anti-":[10],"programmed":[11],"cell":[12],"death":[13],"protein":[14],"1":[15],"(anti-PD-1)":[16],"or":[17,48,197],"its":[18],"ligand":[19],"(PD-L1),":[20],"only":[21],"a":[22,37,93,279,300,319],"minority":[23],"cancer":[25,138,210,326],"patients":[26,57,101,139,211,267],"derive":[27],"long-term":[28],"clinical":[29,162,166,203,207,273,288],"benefit":[30,163,167,204],"from":[31,132],"these":[32,155,286],"agents.":[33],"Therefore,":[34],"there":[35],"is":[36,199,238],"crucial":[38],"need":[39],"to":[40,50,55,62,79,98,305,322],"identify":[41],"novel":[42,287],"and":[43,89,114,123,125,159,175,188,205,247,275,307],"reliable":[44],"biomarkers":[45],"response":[47,97,304],"resistance":[49],"such":[51,314],"treatments":[52],"in":[53,73,100,185,209,243,328],"order":[54],"select":[56],"who":[58],"are":[59],"more":[60],"likely":[61],"benefit.":[63],"Given":[64],"the":[65,69,81,86,108,152,255,294],"known":[66],"role":[67,295],"indoleamine-2,3":[70],"dioxygenase":[71],"(IDO1)":[72],"modulating":[74],"antitumor":[75],"immunity,":[76],"we":[77,106,191,231,258],"aimed":[78],"evaluate":[80],"circulating":[82,111,218,236,297],"IDO1-associated":[83],"metabolites,":[84],"namely":[85],"kynurenine":[87],"(Kyn)":[88],"tryptophan":[90],"(Trp),":[91],"as":[92,299,315],"possible":[94,280],"biomarker":[95,302],"ICIs":[99],"with":[102,141,201,213,224,240,271,330],"solid":[103],"tumors.":[104,253],"Methods:":[105],"analyzed":[107],"levels":[109],"Kyn,":[112],"Trp":[113,158,198,221,264,298,311],"Kyn/Trp":[115,160],"ratio":[116],"plasma":[118],"samples,":[119],"collected":[120],"before":[121],"onset":[122],"on-therapy":[124],"measured":[126],"by":[127,179],"enzyme-linked":[128],"immunosorbent":[129],"assay":[130],"(ELISA),":[131],"two":[133],"independent":[134],"prospective":[135],"cohorts":[136],"treated":[140,212],"ICI":[142,269,306],"(Discovery":[143],"cohort,":[144,147,257],"n=100;":[145],"Validation":[146,189,256],"n=292).":[148],"We":[149,215],"then":[150],"investigated":[151],"correlation":[153],"between":[154],"metabolites":[156],"(Kyn,":[157],"ratio),":[161],"rate":[164],"(durable":[165],"versus":[168],"non-":[169],"durable":[170,202],"benefit),":[171],"progression-free":[172],"survival":[173,177,242],"(PFS)":[174],"overall":[176],"(OS)":[178],"Cox":[180],"proportional":[181],"hazards":[182],"models.":[183],"Results:":[184],"both":[186,244],"Discovery":[187],"cohorts,":[190],"found":[192],"that":[193,217,234,261,309],"elevated":[194],"baseline":[195],"level":[196,219,237,265],"associated":[200,239],"better":[206],"outcome":[208,274],"ICI.":[214,331],"observed":[216],"inversely":[222],"correlates":[223,270],"PD-L1":[225,245],"tumor":[226],"expression.":[227],"By":[228],"subgroup":[229],"analysis,":[230],"also":[232,259],"showed":[233],"high":[235],"prolonged":[241],"negative":[246],"low":[248],"CD8":[249],"T-cell":[250],"density":[251],"within":[252],"In":[254],"demonstrated":[260],"decrease":[262],"among":[266],"receiving":[268],"worse":[272],"shorter":[276],"survival,":[277],"suggesting":[278],"mechanism":[281],"primary":[283],"resistance.":[284],"Conclusion:":[285],"findings":[289],"bring":[290],"strong":[291],"evidence":[292],"for":[293],"potential":[301],"suggest":[308],"catabolic":[312],"pathway,":[313],"IDO1,":[316],"may":[317],"represent":[318],"promising":[320],"approach":[321],"improve":[323],"efficacy":[324],"immunotherapy":[327],"combination":[329]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W6983467665","counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2025-10-10T00:00:00"}
